{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-001684","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2023-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.005017+00:00","generated_at":"2026-06-19T04:59:49.026816+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Editas Medicine reports Q4 2022 net loss $60.7M; advances EDIT-301 trials, sells iNK franchise to Shoreline","bullets":["Q4 2022 net loss $60.7M ($0.88/share) vs $41.4M ($0.61) in Q4 2021; full year net loss $220.4M ($3.21).","Cash $437.4M at Dec 31, 2022, down from $619.9M a year ago; expects to fund operations into 2025.","EDIT-301 for SCD: parallel patient dosing started in RUBY trial; on track to dose 20 patients by year-end, clinical update by mid-2023.","Entered definitive agreement to sell iNK cell franchise and license SLEEK/AsCas12a technologies to Shoreline Biosciences.","BMS opted into three additional gene editing programs and declared one new development candidate under collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-001684","json":"https://secwatch.observer/filing/0001558370-23-001684.json","markdown":"https://secwatch.observer/filing/0001558370-23-001684.md","text":"https://secwatch.observer/filing/0001558370-23-001684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000155837023001684/0001558370-23-001684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000155837023001684/edit-20230222x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T04:59:49.026816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a646331bfa2f760b856e8a4459d276e5c474e1a","claim":"Editas Medicine, Inc. reported the full year 2022 results: revenue $19.7 million, net income $220.4 million, EPS $3.21 per share.","evidence_excerpt":"million, or $3.21 per share, compared to $192.5 million, or $2.85 per share, for the same period in 2021. ​ ● Collaboration and other research and development revenues were $19.7 million for 2022, compared to $25.5 million for 2021. The $5.8 million decrease was primarily attributable decreased revenue recognized in the year ended December 31, 2022 related to the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650664/000155837023001684/0001558370-23-001684-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2022"},{"label":"Revenue","value":"$19.7 million"},{"label":"Net income","value":"$220.4 million"},{"label":"EPS","value":"$3.21 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"268e122065d0369661cd946dae9cfb574fe5a47d","claim":"Editas Medicine, Inc. reported the three months ended December 31, 2022 results: revenue $6.5 million, net income $60.7 million, EPS $0.88 per share.","evidence_excerpt":"to net loss of $41.4 million, or $0.61 per share, for the same period in 2021. ​ ● Collaboration and other research and development revenues decreased by $6.0 million to $6.5 million for the three months ended December 31, 2022, compared to $12.5 million for the same period in 2021. The decrease was primarily attributable to a decrease in collaboration","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650664/000155837023001684/0001558370-23-001684-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Revenue","value":"$6.5 million"},{"label":"Net income","value":"$60.7 million"},{"label":"EPS","value":"$0.88 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}